Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.
about
Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted TherapiesThe choice of regimens based on bortezomib for patients with newly diagnosed multiple myelomaA phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myelomaPhase I/II study of bortezomib-melphalan-prednisolone for previously untreated Japanese patients with multiple myeloma.Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.Bortezomib in multiple myeloma: systematic review and clinical considerations.Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trialApproach to the treatment of multiple myeloma: a clash of philosophies.Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma.Novel agent induction therapy alone or followed by autologous stem cell transplantation in younger patients with multiple myeloma: A single-center retrospective study of 114 cases.The interaction between oral melphalan and gastric antisecretory drugs: Impact on clinical efficacy and toxicity.Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation.The long-term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years.Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in OncologyA CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma.Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma.How best to use new therapies in multiple myeloma.Multiple myeloma treatment strategies with novel agents in 2011: a European perspectiveManaging multiple myeloma in the elderly: are we making progress?Bortezomib for previously untreated multiple myeloma.Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.Novel treatment paradigm for elderly patients with multiple myeloma.Experimental approaches in the treatment of multiple myeloma.Bortezomib for the treatment of previously untreated multiple myeloma.Association of response endpoints with survival outcomes in multiple myeloma.Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.Myeloma bone disease: pathogenesis, current treatments and future targets.Advances in multiple myeloma therapy during two past decades.Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma.Advances in treatment for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation.Standardisation of minimal residual disease in multiple myeloma.Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902).Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma.Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent.Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma (TUBA study).Failure to achieve early disease response is associated with inferior survival in patients with newly diagnosed multiple myeloma.Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myeloma.
P2860
Q27026478-8675C9F0-23B1-48AD-B06B-6A8691508FE0Q28539605-AB4FCDCD-12FB-4640-A1D1-1984B2E91178Q33401596-999E2C1D-7F07-405A-8CD3-C8664FF23FA4Q33406992-A7BFBBDA-304B-4C9F-9A9D-53E9A925EFE5Q33437691-56EB0F1A-D32D-43D8-8158-4FEB89E671B2Q33982728-376AABA1-3D8D-460B-8D5E-3AF07B0F2EC6Q35125893-52A71FA1-EF2D-44A8-B967-191AF58785A4Q35230189-6AFC45F5-F412-45B0-8EB1-BA0DCF1A6C00Q35809982-028F2190-7416-430C-A2EF-A8860CE27113Q36254255-46D0A772-39B7-431B-A1AB-EB822A600D9DQ36502820-B822CCC3-26F0-4392-9BB8-C1162EAABAA2Q36523810-4D6330DB-4982-4ADB-AC21-895C52364F9AQ36536365-C2CD899D-F16C-4A6D-8D08-0C79D6E2D3F8Q36800105-2142B807-8639-49D5-9083-31C3BC049AD5Q36963203-8790FBBB-4584-4A6C-BD96-759870CC0857Q37032148-1C4109DE-3832-4C70-858E-B4F4C02C8D19Q37057028-7A2F84BD-16E4-49DD-A86D-471B6010629FQ37411236-FB32126F-1D99-4599-A9A3-15D4B18B21FEQ37723000-A2357E9F-26AD-4F8D-9AFC-104A1B11D67EQ37858327-9B667560-51BA-4F37-A60A-2AE3AC4BA8ABQ37888716-1400274F-48E9-4ADF-9C79-FB9DA8212948Q37937699-529AFA1B-C4D6-40ED-9E4B-AAF9E2FFFF47Q37949201-9F2FCADB-026D-478A-860B-91ECAD10AC30Q37995195-54478FB7-DE3A-49A4-B795-03F9B766C393Q38095958-F55D4560-7BFE-480E-AB39-EA9600761231Q38096055-0DAD819F-B041-4DC0-A25F-5ED7B752B6CFQ38122624-92188ACF-06A6-477C-9DD5-B47AB5896E72Q38148272-C4F82DC9-DC54-43CA-A25D-CBE2AB513C50Q38246241-B2460DC9-ED2B-43E3-AA53-7DB921492462Q38248293-4A619195-879B-481F-ACF1-7BC98D14B5F2Q38555091-4A004A32-1DB6-499F-9E47-07EAC5E5716EQ38833538-ED8244FA-2DFE-42F3-B736-0A2C2A94E6E5Q39410899-73D63F08-2C13-4B20-B8BF-9A576A412F13Q40818284-7F84B845-1953-4955-BD7A-7977E79B59A2Q44558771-3240EE20-6696-4E11-80E4-56BC2447EB41Q47552083-3064B0DF-8FEB-496F-8FE8-61E0C0A5A10CQ47775860-4B02CE45-8E12-46E8-81DD-1AF386046F27Q48150171-70CED9D5-CE9B-4EFC-A8AF-D188C9754A0AQ48459753-781BEB6C-0089-44A1-B6D1-08B017B2ED41Q51833653-50E08FE9-890E-4B4A-BEC6-6B32372806FF
P2860
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Superior outcomes associated w ...... e versus melphalan-prednisone.
@en
Superior outcomes associated w ...... e versus melphalan-prednisone.
@nl
type
label
Superior outcomes associated w ...... e versus melphalan-prednisone.
@en
Superior outcomes associated w ...... e versus melphalan-prednisone.
@nl
prefLabel
Superior outcomes associated w ...... e versus melphalan-prednisone.
@en
Superior outcomes associated w ...... e versus melphalan-prednisone.
@nl
P2093
P50
P1433
P1476
Superior outcomes associated w ...... e versus melphalan-prednisone.
@en
P2093
Alain Kentos
Anatoly Golenkov
Andrew Cakana
Dixie-Lee Esseltine
Helgi van de Velde
Jean-Luc Harousseau
Jesús F San Miguel
Maria-Victoria Mateos
Martin Kropff
P304
P356
10.1182/BLOOD-2010-03-275800
P407
P577
2010-07-13T00:00:00Z